<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00482430</url>
  </required_header>
  <id_info>
    <org_study_id>0557-027</org_study_id>
    <secondary_id>MK0557-027</secondary_id>
    <secondary_id>2007_520</secondary_id>
    <nct_id>NCT00482430</nct_id>
  </id_info>
  <brief_title>MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)</brief_title>
  <official_title>A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and effectiveness of an investigational
      drug for the treatment of cognitive impairment in patients with schizophrenia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline at 4 weeks of treatment on a sequence of cognitive tests and that MK0557 generally well tolerated</measure>
    <time_frame>at 4 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline at 4 weeks of treatment on neuropsychological tests for executive functioning, episodic memory and working memory</measure>
    <time_frame>at 4 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Paranoid Schizophrenia</condition>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MK0557 10mg tablet qd, crossing over to MK0557 Pbo tablet qd.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MK0557 Pbo tablet qd, crossing over to MK0557 10mg tablet qd.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK0557</intervention_name>
    <description>MK0557 10mg tablet qd for a 15-wk treatment period</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo (unspecified)</intervention_name>
    <description>MK0557 Pbo tablet qd for a 15-wk treatment period</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is clinically stable, on current antipsychotic medication for at least 3
             months and current dose for 2 months

          -  Patient has a 6th grade reading level or better and has completed at least 6 years of
             formal education

          -  Females are not pregnant, and those who can have children agree to remain abstinent or
             use acceptable birth control throughout study

          -  Patient has had a stable living arrangement for at least 3 months prior to study start

          -  Patient is in general good health based on screening assessments

        Exclusion Criteria:

          -  Patient has a major disease/disorder that may interfere with cognitive testing (such
             as mental retardation) and/or pose a risk upon study participation

          -  Patient has a history of head trauma with loss of consciousness greater than 15
             minutes

          -  Patient has had warfarin treatment, MAO inhibitors, clonazepam, clozapine or St.
             John's wort within 1 month of screening

          -  Patient has had ECT treatment within 6 months of screening

          -  Patient requires treatment with antihistamines or certain other medications listed in
             the protocol

          -  Patient has a history of liver disease that has been active within the last 2 years,
             or a history of cancer within past 5 years

          -  Patient has a history of alcohol or drug dependence within past year or alcohol or
             drug abuse within 3 months of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>India</country>
    <country>Malaysia</country>
  </removed_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2007</study_first_submitted>
  <study_first_submitted_qc>June 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2007</study_first_posted>
  <last_update_submitted>August 20, 2015</last_update_submitted>
  <last_update_submitted_qc>August 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Undifferentiated schizophrenia</keyword>
  <keyword>Residual schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
    <mesh_term>Schizophrenia, Paranoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

